BLTE Belite Bio Inc ADR

$64.40

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Belite Bio Inc ADR

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California.

Website: https://www.belitebio.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1889109
Address
12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA, CA
Valuation
Market Cap
$1.82B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
12.49
Performance
EPS
$-1.18
Dividend Yield
—
Profit Margin
0.00%
ROE
-30.60%
Technicals
50D MA
$60.94
200D MA
$58.26
52W High
$86.53
52W Low
$32.50
Fundamentals
Shares Outstanding
32M
Target Price
$85.00
Beta
-1.52

BLTE EPS Estimates vs Actual

● Estimated
● Actual

BLTE News & Sentiment

Aug 11, 2025 • Benzinga SOMEWHAT-BULLISH
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Belite Bio ( NASDAQ:BLTE )
Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease ( STGD1 ) by the U.S. Food and Drug Administration ( FDA ) DRAGON trial completion expected by Q4 2025 ( including a three-month follow-up period )
Aug 11, 2025 • GlobeNewswire NEUTRAL
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Belite Bio, Inc ( NASDAQ: BLTE ) , a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the ...
Aug 07, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Belite Bio Announces Registered Direct Offering of $15 Million
SAN DIEGO, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Belite Bio, Inc ( "BLTE" or the "Company" ) ( Nasdaq: BLTE ) , a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that ...
Aug 06, 2025 • Benzinga NEUTRAL
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference - Belite Bio ( NASDAQ:BLTE )
SAN DIEGO, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Belite Bio, Inc BLTE, a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will ...
Aug 04, 2025 • Zacks Commentary NEUTRAL
New Strong Sell Stocks for August 4th
BBCP, BLTE and CWH have been added to the Zacks Rank #5 (Strong Sell) List on August 4, 2025.
Jul 22, 2025 • Zacks Commentary NEUTRAL
New Strong Sell Stocks for July 22nd
BLTE, DDD and ANNX have been added to the Zacks Rank #5 (Strong Sell) List on July 22, 2025.
Sentiment Snapshot

Average Sentiment Score:

0.169
50 articles with scored sentiment

Overall Sentiment:

Bullish

BLTE Reported Earnings

Mar 17, 2025
Dec 31, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.32
  • Estimate: $-0.31
  • Whisper: —
  • Surprise %: -4.1%
Nov 12, 2024
Sep 30, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: 6.7%
Aug 12, 2024
Jun 30, 2024 (Pre market)
-0.05 Surprise
  • Reported EPS: $-0.31
  • Estimate: $-0.26
  • Whisper: —
  • Surprise %: -19.2%
May 13, 2024
Mar 31, 2024 (Post market)
0.01 Surprise
  • Reported EPS: $-0.27
  • Estimate: $-0.28
  • Whisper: —
  • Surprise %: 3.6%
Mar 11, 2024
Dec 31, 2023 (Post market)
0.05 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: 16.7%
Nov 13, 2023
Sep 30, 2023 (Post market)
-0.08 Surprise
  • Reported EPS: $-0.40
  • Estimate: $-0.32
  • Whisper: —
  • Surprise %: -25.0%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $-0.26
  • Estimate: $-0.30
  • Whisper: —
  • Surprise %: 13.3%
May 10, 2023
Mar 31, 2023 (Post market)
-0.13 Surprise
  • Reported EPS: $-0.33
  • Estimate: $-0.20
  • Whisper: —
  • Surprise %: -65.0%
Mar 31, 2023
Dec 31, 2022 (Post market)
-0.2 Surprise
  • Reported EPS: $-0.37
  • Estimate: $-0.17
  • Whisper: —
  • Surprise %: -117.7%

Financials